English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Originada por el Mycobacterium tuberculosis. Esto llevo a la creacion de una vacuna que se presento oficialmente en 1924 y que se conoce como Bacilo Calmette y Guerin (BCG), desde entonces se la ha utilizado. Sin embargo, ha habido numerosas investigaciones sobre su eficacia y otros factores relacionados que han mostrado desequilibrio. Varios paises recomiendan el uso de esta vacuna en los recien nacidos, pero en el caso de Ecuador se ha dejado de recomendar su aplicacion, a pesar de que no existan datos en relacion a la eficacia de la vacuna en dicho pais. Otros estudios demuestran que el conocimiento de las personas acerca de la enfermedad es muy pobre, permitiendo asi que esta pueda propagarse con mayor facilidad, debido a que la persona infectada no conoce el tipo de sintomatologia que la Tuberculosis genera. Este articulo tiene el objetivo de conocer el estado actual de la eficiencia y seguridad de la BCG mediante la revision y analisis de articulos recopilados relacionados al uso de la vacuna y su eficacia en la poblacion investigada. Abstract TB is the second leading cause of death from an infectious agent, disease caused by Mycobacterium tuberculosis. It allowed the creation of a vaccine officially launched in 1924 and known as Bacillus Calmette-Guerin (BCG) used since then. However, there has been extensive research on its effectiveness and other related factors have shown an imbalance. Several countries recommend the use of this vaccine in infants, but in the case of Ecuador has failed to suggest its application, although there are no data regarding the efficacy of the vaccine in that country. Other studies show that the knowledge of people about the disease is destitute, thus allowing this could spread more quickly because the infected person does not know the type of symptoms that generates Tuberculosis. This article aims to identify the current status of the efficiency and safety of BCG through review and analysis of collected items related to the use of the vaccine and its effectiveness in the research population.

Vacuna contra la tuberculosis BCG: Eficacia y efectos adversos / BCG vaccine against tuberculosis: Efficacy and adverse effects